The relative buffering capacities of saliva and moist snuff: Implications for nicotine absorption

被引:18
作者
Ciolino, LA [1 ]
McCauley, HA [1 ]
Fraser, DB [1 ]
Wolnik, KA [1 ]
机构
[1] US FDA, Forens Chem Ctr, Cincinnati, OH 45237 USA
关键词
D O I
10.1093/jat/25.1.15
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Commercial moist snuff products are used by placing a portion of tobacco inside the mouth between the inner cheek or lip and gum. Nicotine is absorbed into the blood stream via transfer across various oral membranes including the buccal mucosa (cheek lining). The resulting salivary pH when a given moist snuff product is placed in the mouth is an important factor for nicotine absorption because it will affect the proportion of free base nicotine that is readily available for absorption. The resulting salivary pH for a given moist snuff product will be determined in part by the relative acid-base buffering capacities of the saliva and moist snuff, as well as the pHs of the saliva and moist snuff prior to coming in contact with one another. In the current study, the acid-base buffering capacities (μeq/g) of a series of commercial moist snuff products were determined and compared to the acid-base buffering capacity for unstimulated, whole human saliva. The buffering capacities of the moist snuff products were determined to be 10-20 times higher than the buffering capacity of human saliva. The resulting salivary pH ranges after contact between an artifical saliva and the various moist snuff products were also determined; the results were used to predict the proportion of free base nicotine that can be expected to occur in the mouth during the first few minutes of product use. These studies provide a basis for examining and understanding the effects that moist snuff product pHs and buffering capacities may be expected to have on nicotine absorption.
引用
收藏
页码:15 / 25
页数:11
相关论文
共 42 条
[1]  
ALBRECHTSEN S, 1999, Patent No. 5939100
[2]   INFLUENCE OF PH ON THE BUCCAL ABSORPTION OF MORPHINE-SULFATE AND ITS MAJOR METABOLITE, MORPHINE-3-GLUCURONIDE [J].
ALSAYEDOMAR, O ;
JOHNSTON, A ;
TURNER, P .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1987, 39 (11) :934-935
[3]   ORAL MUCOSAL CHANGES AND NICOTINE DISPOSITION IN USERS OF SWEDISH SMOKELESS TOBACCO PRODUCTS - A COMPARATIVE-STUDY [J].
ANDERSSON, G ;
BJORNBERG, G ;
CURVALL, M .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 1994, 23 (04) :161-167
[4]  
ARBAB AG, 1971, BRIT J PHARMACOL, V43, pP479
[5]  
BAKER RW, 1992, Patent No. 5135753
[6]  
BAKER RW, 1997, Patent No. 5593684
[7]   HUMAN BUCCAL ABSORPTION OF FLURBIPROFEN [J].
BARSUHN, CL ;
OLANOFF, LS ;
GLEASON, DD ;
ADKINS, EL ;
HO, NFH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :225-231
[8]   POSSIBLE RELATION BETWEEN PKA1 AND LIPID SOLUBILITY AND AMOUNTS EXCRETED IN URINE OF SOME TOBACCO ALKALOIDS GIVEN TO MAN [J].
BECKETT, AH ;
JENNER, P ;
GORROD, JW .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1972, 24 (02) :115-&
[9]  
BECKETT AH, 1967, J PHARM PHARMACOL, VS 19, pS31
[10]   NICOTINE ABSORPTION AND CARDIOVASCULAR EFFECTS WITH SMOKELESS TOBACCO USE - COMPARISON WITH CIGARETTES AND NICOTINE GUM [J].
BENOWITZ, NL ;
PORCHET, H ;
SHEINER, L ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (01) :23-28